GlycoMimetics (NASDAQ:GLYC – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01, Zacks reports.
GlycoMimetics Price Performance
Shares of NASDAQ:GLYC opened at $0.25 on Friday. GlycoMimetics has a fifty-two week low of $0.14 and a fifty-two week high of $0.63. The business has a 50-day moving average of $0.24 and a two-hundred day moving average of $0.28. The stock has a market capitalization of $16.12 million, a P/E ratio of -0.42 and a beta of 1.70.
Analyst Ratings Changes
GLYC has been the subject of several research reports. Cantor Fitzgerald initiated coverage on GlycoMimetics in a report on Friday, March 21st. They set an “overweight” rating for the company. StockNews.com began coverage on shares of GlycoMimetics in a research note on Friday, May 9th. They issued a “sell” rating for the company.
About GlycoMimetics
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Read More
- Five stocks we like better than GlycoMimetics
- What Does a Stock Split Mean?
- Lockheed Martin: A Top Defense Pick in 2025
- What is the Nasdaq? Complete Overview with History
- If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Mid-Cap Stocks Turning Heads in AI, Automation, & Cybersecurity
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
